U.S. Beats Trade Deficit Record, Ends 2022 With $1.19 Trillion Goods Gap
The latest trade figures show historic deficits with Mexico, Canada and Vietnam. Meanwhile, the 2022 deficit with China and the EU is the second largest of all time.
Is the U.S. Still Financing China’s Military Might?
Yes, in many ways the U.S. is funding China’s defense sector through venture capital, portfolio investments, and computer hardware sales to companies on the Entity List.
Pharmaceuticals Are Heavily Outsourced. Can the U.S. Make More of it Here?
The U.S. is increasingly dependent on imports for drugs. One reason: a tax avoidance scheme that pits U.S. manufacturing up against Europe. What can be done about this problem?
Americas Act Addresses Key Failure of Past Trade Deals
U.S. Senator Bill Cassidy (R-LA) has released a discussion draft of a sweeping, ambitious bill titled the “Americas Act”. The bill states its aim to
European Pharma Considers Reshoring from India, China. Where’s the US?
The Covid-19 pandemic gave big pharma big payday. But it also caused the industry to rethink a globalized supply chain centered on Asia. What will it take to reshore at least some generic drugs to the U.S.
Supply Chain Dependence Makes Reshoring Harder – McKinsey
Can the U.S. really bring manufacturing home? A McKinsey study shows that existing concentration of some supply chains will make it hard. Here’s what needs to be done.
Repealing China’s Most Favored Nation Status: A Guide
By Charles Benoit, CPA Trade Counsel In December, the U.S.-China Commission, a group created by Congress to advise on managing the bilateral relationship, formally recommended
Ambassador Bob Lighthizer Tells Laura Ingraham Why the GOP Must Embrace Tariffs and Balanced Trade
Ambassador Bob Lighthizer, the former U.S. Trade Representative in the Trump administration, joined Laura Ingraham on Fox News Channel to discuss trade, the TPP, and
India Drug Maker Aurobindo Keeps Getting Poor Grades by the FDA
One of India’s pharmaceutical labs has run afoul of the FDA many times this year. The U.S. is dependent on foreign labs like Aurobindo for its drug supply. Can the government help change that?
As 2022 Draws to a Close, Globalization is Still Against the Ropes
As 2022 winds down, one thing remains clear, globalization is losing support among policy makers, and even among influencers like Paul Krugman.